DSIP vs Selank
Sleep versus anxiety, and two very different depths of evidence: Selank has small human anxiety trials, while DSIP's basic biology is still unsettled after nearly fifty years.
Short answer
DSIP and Selank both have human clinical data, so the deciding factor is what you want them for. DSIP suits someone focused on sleep and stress, while Selank is aimed at anxiety and focus. For DSIP, sleep reported as normalized in all but one of 7 insomnia patients in an uncontrolled 1984 open trial.
DSIP
Delta sleep-inducing peptide
A 1977 sleep peptide whose gene, receptor and real human benefit remain unconfirmed half a century on; only small, old, inconclusive human data.
Full DSIP evidence reviewSelank
A GABA-modulating anxiolytic that matched benzodiazepines in small Russian trials; the mechanism is credible but the evidence base is thin and single-country.
Full Selank evidence reviewDSIP vs Selank: head to head
- FDA status / approved use
DSIP
Not an approved drug in the US; sold as unregulated research-use-only materialSelank
Reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide- Marketed for
DSIP
Sleep, stressSelank
Anxiety, focus- Outcome areas
DSIP
Sleep; Mood / anxiety / stressSelank
Mood / anxiety / stress; Cognitive function / memory- Evidence grade
DSIP
Clinical dataSelank
Clinical data- How it works
DSIP
Unknown; no DSIP gene, precursor or receptor has been confirmedSelank
Modulates the GABA system without acting as a benzodiazepine- Route and dosing
DSIP
Injectable powder or nasal spray from gray-market sellersSelank
Nasal spray (intranasal)- Headline human result
DSIP
Sleep reported as normalized in all but one of 7 insomnia patients in an uncontrolled 1984 open trialSelank
Matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized- Strongest evidence
DSIP
Kaeser, Eur Neurol 1984DSIP evidence reviewPubMed 6391926Selank
Medvedev, Korsakov J 2015Selank evidence reviewPubMed 26356395- Key safety signal
DSIP
No established safety profile; gray-market vials of unverified identity, dose and puritySelank
No large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern- How it is obtained
DSIP
Sold gray-market as a research chemical; no approved or legitimately compounded human productSelank
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| DSIP | Selank | |
|---|---|---|
| FDA status / approved use | Not an approved drug in the US; sold as unregulated research-use-only material | Reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide |
| Marketed for | Sleep, stress | Anxiety, focus |
| Outcome areas | Sleep; Mood / anxiety / stress | Mood / anxiety / stress; Cognitive function / memory |
| Evidence grade | Clinical data | Clinical data |
| How it works | Unknown; no DSIP gene, precursor or receptor has been confirmed | Modulates the GABA system without acting as a benzodiazepine |
| Route and dosing | Injectable powder or nasal spray from gray-market sellers | Nasal spray (intranasal) |
| Headline human result | Sleep reported as normalized in all but one of 7 insomnia patients in an uncontrolled 1984 open trial | Matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized |
| Strongest evidence | Kaeser, Eur Neurol 1984DSIP evidence reviewPubMed 6391926 | Medvedev, Korsakov J 2015Selank evidence reviewPubMed 26356395 |
| Key safety signal | No established safety profile; gray-market vials of unverified identity, dose and purity | No large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Selank is the better-characterized of the two: a defined tuftsin analog with a GABA-modulating mechanism and small Russian trials that measured it against benzodiazepines. DSIP has no confirmed gene, precursor, or receptor, and its human record is chiefly a 1984 open trial in seven insomnia patients plus scattered 1980s work in pain and withdrawal, with no modern randomized placebo-controlled trial for any indication. Neither is FDA-approved and both reach US buyers as unregulated research-only material. Neither has been compared with the other.
DSIP fits if
DSIP is of interest mainly as a historical research curiosity for readers following the sleep-factor question, not as a sleep therapy.
Selank fits if
Selank is the more grounded read for anyone researching anxiety pharmacology outside the benzodiazepine class.
DSIP vs Selank: common questions
- Is either DSIP or Selank FDA-approved?
- No. DSIP is not an approved drug in the US; sold as unregulated research-use-only material. Selank is reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide.
- Which has stronger human evidence, DSIP or Selank?
- Neither clearly. Both have human clinical data. The key source for DSIP is Kaeser, Eur Neurol 1984; for Selank, it is Medvedev, Korsakov J 2015.
- What are the main safety concerns with DSIP and Selank?
- DSIP has no established safety profile; gray-market vials of unverified identity, dose and purity. Selank has no large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern.
Key studies behind each
DSIP
- Schoenenberger GA, Monnier M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. PubMed 265572
- Kovalzon VM, Strekalova TV. (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. PubMed 16539679
- Kaeser HE. (1984). A clinical trial with DSIP. Eur Neurol. PubMed 6391926
- Uhl D. (1987). Delta sleep-inducing peptide. Effective in sleep disorders, stress, chronic pain and substance dependence? Med Monatsschr Pharm. PubMed 3657697
Selank
- Vyunova TV, Andreeva L, Shevchenko K, et al. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. PubMed 30255741
- Volkova A, Shadrina M, Kolomin T, et al. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. PubMed 26924987
- Zozulya AA, Kost NV, Sokolov OYu, et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. PubMed 11550013
- Doyno CR, White CM. (2021). Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol. PubMed 34396551
The full evidence reviews
- DSIP (delta sleep-inducing peptide): a famous name, an unresolved science
A naturally-occurring nonapeptide named for the delta brain-waves it produced in 1977 rabbits — yet half a century on, its gene, receptor and real human benefit remain unconfirmed. The honest, evidence-first read.
Updated August 2026
- Selank: a non-benzodiazepine anxiolytic peptide, lightly tested
A tuftsin-analog heptapeptide that modulates GABA without being a benzodiazepine — and matched benzodiazepines in small Russian trials. The mechanism is credible; the evidence base is thin.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm DSIP availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: LevelUp RxLevers HealthLibertyLifespanningRxLoop HealthLttl